Skip to main content
. 2003 Aug;77(16):8843–8856. doi: 10.1128/JVI.77.16.8843-8856.2003

FIG. 8.

FIG. 8.

VSV-IFNβ increases the survival of immunocompetent animals harboring metastatic tumors. BALB/c animals (6 to 8 weeks; n = 8) were injected via tail vein with 5 × 104 TS/A cells, followed 2 days later by a single i.v. injection (5 × 107 PFU) of VSV-GFP, VSV-IFNβ, or HI-VSV. Following injection, the survival rates of the animals were monitored. A total of 50% of animals receiving VSV-IFNβ continued to remain disease free after 120 days.